Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This pharmacovigilance study analyzed FAERS data and found that finasteride is more frequently associated with neuropsychiatric reactions like depression and suicide risk, especially in younger men using it for alopecia, compared to dutasteride.

This research found that the new combination drug Predstanormix Duo, with dutasteride and tamsulosin, is bioequivalent to established treatments for benign prostatic hyperplasia, showing similar pharmacokinetics and safety, potentially improving treatment availability and adherence in high-risk patients.

In this study, HDAC inhibitors promoted the differentiation of rat C6 glioma cells through the production of 5α‐reduced neurosteroids, enhancing serotonin-stimulated BDNF gene expression.

This study found that post-finasteride syndrome patients showed a tissue-specific methylation pattern of the SRD5A2 promoter in cerebrospinal fluid, potentially affecting neuroactive steroid levels and related behavioral symptoms.

This study found that the antidepressant-like effect of fluoxetine in mice was only observed when a 5-minute pretest session was conducted, and this effect was blocked by the TSPO antagonist PK11195.

This review examines the cognitive effects of medications for lower urinary tract symptoms and indicates that muscarinic antagonists, particularly oral oxybutynin, pose the highest risk for cognitive impairment.

This review discusses the known effects of medications for benign prostatic hyperplasia on sexual function and mechanisms of dysfunction but reports no new clinical results.

This study found that stimulation with certain neurotransmitters and hormones suggests the involvement of 5α-reduced neurosteroids in glial cell differentiation in rat C6 glioma cells.

This review discusses how 5α-reductase inhibitors affect PSA levels in benign prostatic hyperplasia treatment and their role in prostate cancer screening, but reports no new clinical findings.

This review examines medical literature on postfinasteride syndrome and reports no new results; the authors call for more controlled studies on permanent sexual dysfunction and mood changes linked to 5-alpha-reductase inhibitors.

This study suggests that while treatments like allopregnanolone, trazodone, antipsychotic drugs, and hormonal therapies may offer potential benefits for post-finasteride syndrome, further research is necessary to validate their effectiveness.

This study developed solid lipid nanoparticles for delivering a shRNA-encoding plasmid that effectively reduced 5α-reductase enzyme levels in vitro without significant cytotoxicity, suggesting potential therapeutic applications.

This study found that finasteride significantly reduced levodopa-induced dyskinesia in both male and female rats without diminishing l-DOPA's motor benefits, indicating potential for clinical trials in Parkinson's patients.

Finasteride is not proven to cause depression or suicide, and careful patient monitoring is advised.

This paper reviews the growing use of psychotropic drugs in dermatology due to the link between mental states and skin conditions but does not present new clinical findings.

This case report suggests that discontinuing finasteride, which may affect neurosteroids synthesis, improved seizure control in a woman with temporal lobe seizures.

This review discusses the risk of central nervous side effects, such as dementia and depression, from drugs used to treat lower urinary symptoms related to benign prostatic hyperplasia, and highlights inconsistent evidence across different medications.

This study explores the controversial condition known as post‐finasteride syndrome, observed in some men who experience lasting sexual, neurological, and psychological side effects after stopping finasteride, emphasizing its rarity and the lack of proven treatments.

This correction clarifies the affiliations of researcher D. Piomelli in a case report on symptom improvement in a chronic psychotic patient treated with finasteride, without presenting new research findings.

This study found that Golvatinib, Gliquidone, and Dihydroergotamine may inhibit the binding of SARS-CoV-2's Nsp1 protein to the host ribosomal subunit, suggesting potential as treatments against COVID-19 variants.

This study reported that in rat retinas under high pressure, allopregnanolone synthesis increased and helped reduce pressure-induced damage through GABAA receptors, suggesting potential therapeutic use in glaucoma.

Off-label drug use can be risky and requires careful consideration to ensure patient safety.

This study developed a new clustering model to improve detection of drug-induced cognitive disorder risk signals, finding that it identified drugs with moderate risk signals, like Carbidopa/Levodopa, missed by traditional methods, enhancing clinical assessment comprehensiveness.

This article reviews 12 newly approved drugs with pediatric indications from 2001, discussing their clinical importance for general pediatricians, but reports no new clinical results.

This review focuses on neuroactive steroids' influence on GABA-ergic signaling and discusses challenges in developing them for various therapeutic uses, citing recent excitement from FDA approval of allopregnanolone for postpartum depression but reporting no new results.

In this animal study, finasteride exposure led to impaired spermatogenesis in rats, while the novel compound DA-9401, derived from three medicinal herbs, demonstrated potential in improving sperm parameters and reducing testicular apoptosis when used alone or with finasteride.

This study suggests that stress may worsen Tourette syndrome symptoms in mice by increasing allopregnanolone synthesis, with findings supporting finasteride as a potential treatment to manage symptom fluctuations.

This case report describes a young girl with a rare association of anti-SRP positive necrotizing autoimmune myopathy and systemic lupus erythematosus, who responded well to corticosteroid treatment.